| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1474-4422(17)30379-4 |
| P698 | PubMed publication ID | 29122522 |
| P2093 | author name string | Marinos C Dalakas | |
| P2860 | cites work | The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile | Q35832478 |
| Advances in the diagnosis, pathogenesis and treatment of CIDP. | Q37918316 | ||
| Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose | Q37942415 | ||
| Pathogenesis of immune-mediated neuropathies | Q38221906 | ||
| Optimizing IgG therapy in chronic autoimmune neuropathies: a hypothesis driven approach | Q38270717 | ||
| Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease | Q38390889 | ||
| Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial | Q80454073 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 20-21 | |
| P577 | publication date | 2017-11-06 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy | |
| P478 | volume | 17 |
Search more.